article thumbnail

Outcome of antithrombotic therapy in cancer patients with catheter-related thrombosis: a systematic review

Frontiers in Cardiovascular Medicine

Introduction The guidelines' recommendations for anticoagulation in cancer patients with catheter-related thrombosis are unclear. The aim of this systematic review was to assess anticoagulation management in cancer patients with catheter-related thrombosis (CRT) based on previously published studies.

article thumbnail

Cancer-associated thoracic aorta arterial thrombosis: case report and review of the literature

Frontiers in Cardiovascular Medicine

BackgroundArterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.

article thumbnail

API-CAT: Extended Anticoagulant Therapy With Reduced-Dose Apixaban Noninferior to Full-Dose in Patients With Active Cancer and VTE

American College of Cardiology

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25

Cancer 65
article thumbnail

Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial

Journal of Cardiothoracic Surgery

To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer sur.

article thumbnail

Cancer-Associated Venous Thromboembolism — Beyond 6 Months

The New England Journal of Medicine

Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than in the general population. More than 20 years have passed since Lee et al.1 1 reported the results of the.

Cancer 52
article thumbnail

Anticoagulation Management of Distal Deep Vein Thrombosis in Cancer Patients

American College of Cardiology

Active cancer is a strong risk factor for venous thromboembolism (VTE) events and recurrent events following discontinuation of anticoagulation therapy, and cancer patients are also at a heightened risk for bleeding complications related to anticoagulation treatment.

Cancer 55
article thumbnail

Upper extremity phlegmasia cerulea dolens complicating supra vena cava embolism in a cervical cancer patient: case report

Frontiers in Cardiovascular Medicine

Phlegmasia cerulea dolens (PCD) is a rare yet severe complication of deep vein thrombosis (DVT), characterized by a high amputation rate and mortality. Early diagnosis and treatment are crucial in managing this condition. PCD predominantly affects the lower extremities rather than the upper extremities.